GuidelineChest2012
Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.
Guideline in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Guideline
- Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2014Trial
- Advances in management of sarcoidosis-associated fatigue: A narrative review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Article
- Normalization of CEA, CA15-3, and CA27-29 Tumor Markers Following Single Lung Transplant in a Patient With a History of Early-Stage Breast Cancer and Idiopathic Pulmonary Fibrosis: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- An update on hypophysitis.Nature reviews. Endocrinology · 2026Review
- Risk Factors for Acute Rejection in Pediatric Lung Transplantation and Its Impact on Graft Failure.Pediatric pulmonology · 2026Article
- Cryobiopsy at the dawn of fibrosis: unlocking early diagnosis and therapeutic windows.Frontiers in medicine · 2026Review
- Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma.Frontiers in medicine · 2026Review
- Article
- Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.Journal of clinical medicine · 2025Review
- A Case Series and Review of Hydroxychloroquine Toxicity and Monitoring: How Do We Dose Hydroxychloroquine?Cureus · 2025Article
- Tacrolimus monitoring parameters are not associated with acute cellular rejection following lung transplantation.European journal of clinical pharmacology · 2021Article
- Acute exacerbations of interstitial lung disease: what is the best treatment?Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2021Article
- Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Review
- The Diagnosis and Treatment of Antisynthetase Syndrome.Clinical pulmonary medicine · 2016Article
- Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease.Pulmonary pharmacology & therapeutics · 2016Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesImmunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and inflammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents.
methodsCommittee members developed and refined a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline.
conclusionsIt is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.